Navigation Links
Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave®
Date:9/20/2011

SAN DIEGO, Sept. 20, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced today that following a recent meeting with senior officials in FDA's Office of New Drugs (OND), the Company received written correspondence detailing OND's design requirements for a cardiovascular outcomes trial (CVOT) for Contrave® that would address the Complete Response Letter (CRL) received in January 2011. Orexigen believes that these design requirements are reasonable and feasible and provide the certainty required to reinitiate development of Contrave.  Importantly, FDA stated that "if the interim analysis meets the specified criteria to exclude an unacceptable increased cardiovascular (CV) risk, the drug could be approved." Furthermore, FDA stated that "While we still plan to convene a public advisory committee meeting to discuss topics related to obesity drug development early next year, that meeting will not impact on the advice provided in this letter and the agency will honor the advice provided."

"We have been working with clinical experts, advocacy groups, and our partner, Takeda, throughout this process and are pleased with the feedback provided by FDA that identified a very clear and feasible path forward for this important therapy," said Michael Narachi, President and CEO of Orexigen.

The most important aspects of the CVOT design outlined by FDA include that the trial be powered based on an intent-to-treat analysis, along with criteria for interpreting the results at interim and final analyses that are similar to those that are applied to diabetes drugs. Specifically, FDA advised that the trial enroll a population of overweight and obese patients with an estimated background rate of 1.0-1.5% annual risk of major CV events. In this population, the upper bound of the 95% confidence interval should exclude a hazard ratio of 2.0 and 1.4 at the int
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
2. Orexigen® Therapeutics Provides a Regulatory Update on Contrave® NDA
3. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
4. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
5. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
6. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
7. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
10. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
11. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... MILAN , April 27, 2015  USL di ... Italian province of Reggio Emilia, has implemented Zebra ... throughout the hospital. The Wireless Network Solution ... patients, medical records securely and in real time via ... available at all times. Zebra also provides employee and ...
(Date:4/27/2015)... SAN DIEGO , April 27, 2015  Agena Bioscience ... (CSP) for Agena Bioscience,s MassARRAY platform in China ... at unprecedented speed. It is a hotbed for practical, meaningful ... China and for the rest of the world. ... community in China ," said Peter ...
(Date:4/27/2015)... -- China Jo-Jo Drugstores, Inc. (NASDAQ CM: ... leading China-based retail and wholesale distributor that offers pharmaceutical ... pharmacies, today announced its subsidiary, Hangzhou Jiuzhou Grand Pharmacy ... sales incentive agreement with Wyeth Pharmaceutical Company, Ltd. ("Wyeth"), ... of Pfizer Inc. (NYSE: PFE ) (the ...
Breaking Medicine Technology:Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 2Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 3Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 4Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 5Agena Bioscience Names Bioyong Technology as Fifth Certified Service Provider in China 2China Jo-Jo Drugstore Signed a New Sales Incentive Agreement with Wyeth Pharmaceutical, a Subsidiary of Pfizer 2China Jo-Jo Drugstore Signed a New Sales Incentive Agreement with Wyeth Pharmaceutical, a Subsidiary of Pfizer 3China Jo-Jo Drugstore Signed a New Sales Incentive Agreement with Wyeth Pharmaceutical, a Subsidiary of Pfizer 4
... Disease Week ... 2008, ... today that it has initiated the Phase 2 clinical,development program of MDX-1100, ... ulcerative colitis (UC) and,rheumatoid arthritis (RA). MDX-1100 could potentially treat UC and ...
... Thailand, May 9 An emergency,veterinary team from the ... stand-by in Thailand awaiting authority to enter cyclone struck,Myanmar ... of animals,that human survivors depend on for food and ... The Food and Agriculture,Organization of the United Nations (FAO) ...
Cached Medicine Technology:Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 2Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 3Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 4Animals That Cyclone Survivors Depend on Need Help Now 2
(Date:4/27/2015)... Doctors on Liens has been the go ... over twenty years. So when attorneys of personal injury victims ... the Fresno area , Doctors on Liens responded with the ... medical specialists. With a medical group of chiropractors, an ... is now helping more personal injury victims than ever. ...
(Date:4/27/2015)... Columbus, OH (PRWEB) April 27, 2015 ... insurance to help his clients feel secure, but also helps ... a.m. to 7 p.m., Douglas will be manning a booth ... Expo Center, Lausche Building, 717 E. 17th Ave., Columbus, Ohio. ... this worthy event that will feature hundreds of adoptable pets ...
(Date:4/27/2015)... On May 15, Mount Soma Ashram students ... to raise awareness of the vision of Mount Soma; ... Temple. Ironically, when many of these people moved to ... they were leaving the social and technological world behind. ... meditation, service to a higher cause, deep introspection, and ...
(Date:4/27/2015)... 27, 2015 Attorney Dan Newlin, of the ... and protecting his clients, took that commitment to a whole ... code which makes it easier for existing and potential clients ... building his brand and added value to the firm’s services, ... area where Newlin has law offices. , “I knew the ...
(Date:4/27/2015)... Texas has saved $433 million by ... to providing drug offenders with addiction treatment, according to ... 8th. Several states, including Massachusetts, are considering adopting justice ... has formed community recovery programs to help redress rampant ... of State Governments WA, ID, NE, KS, MI, ...
Breaking Medicine News(10 mins):Health News:Eminent Doctor Joins Forces with Doctors on Liens in Fresno 2Health News:Farmers Insurance Agent Douglas Fitzpatrick Ensures Pets Find Homes 2Health News:Mount Soma Monks Do Social Media 2Health News:Dan Newlin Hashtags It With #Dan 2Health News:Texas Saves $443 Million Embracing Justice Reinvestment for Drug Charges 2Health News:Texas Saves $443 Million Embracing Justice Reinvestment for Drug Charges 3
... Dr Andrew Wakefield, finds firstly that MMR vaccine was found ... others findings now supports// it saying (measles has been found ... ,Dr Stephen Walker, of Wake Forest University ... between autistic children with bowel disease and measles virus and ...
... Dr. Ronald E. Cranford, 65, a neurologist and brain injury ... establish clearer standards to determine whether a patient was in ... to his family the cause of death was complications of ... advocate for the right of terminally ill patients to end ...
... has revealed that preterm babies between 34 and 36 weeks ... disorder. ,Babies born at even less ... ADHD. ,The study conducted by Danish Researchers is based on ... in Childhood which revealed an increased occurrence of ADHD ...
... India on par with South Africa. It has been revealed ... HIV infected people//. ,The number of people living ... Global AIDS Epidemic is 5.7 million. This estimate has included ... whereupon the Indian HIV infected population number has risen by ...
... The provincial government has permitted the Alberta pharmacists to ... But drugs under the narcotics category or addictive drugs ... beginning fall, pharmacists who have undergone a full-fledged training ... high blood pressure. ,This is slated to spruce ...
... World Congress on Osteoporosis (IOF WCO), the world's largest ... opened on Friday June 2, in Toronto, Canada//. ... Scientific Committee, noted that this year's congress attracted 720 ... congress held in 2004 in Rio de Janeiro, Brazil. ...
Cached Medicine News:Health News:Renowned Doctor Passes Away 2Health News:Premature Birth Could Lead to ADHD 2
Inquire...
Inquire...
Inquire...
The modular, high-end stereomicroscope; meets even the most critical demands in research and quality control provides high-contrast images with excellent depth of field and color fidelity...
Medicine Products: